Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ono's S1P receptor agonist meets RRMS endpoint

Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528) said once-daily 0.05, 0.1 and 0.15 mg doses of oral

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE